| News & Announcements | Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for Independence Commercial Members (Updated December 15, 2022) | | | | | | 12/15/2022 | | | |
| News & Announcements | 01/01/2023 CPT and HCPCS Quarterly Update Coverage Determinations for Commercial Products | | | | | | 12/30/2022 | | | |
| Notifications | Noninvasive Respiratory Assist Devices (RADs): Continuous Positive Airway Pressure (CPAP) Devices, Auto-Adjusting Positive Airway Pressure (APAP) and Bi-Level Devices | 05.00.30n | 12/2/2022 9:00 AM | 1/2/2023 | | | 12/2/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Notifications | eviCore Lab Management (Independence) | 06.02.52aa | 12/2/2022 11:00 AM | 1/1/2023 | | | 12/2/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Notifications | Neuromuscular Electrical Stimulators (NMES) and Functional Electrical Stimulators (FES) | 05.00.73f | 12/2/2022 1:00 PM | 1/2/2023 | | | 12/2/2022 | Coverage and/or Reimbursement Position;Medical Coding | | |
| Notifications | Insertion of Implantable Infusion Pumps | 11.15.03l | 12/16/2022 9:00 AM | 1/16/2023 | | | 12/16/2022 | Medical Coding;General Description, Guidelines, or Informational Update | | |
| New Policies | Rapid Whole Exome Sequencing (rWES) and Rapid Whole Genome Sequencing (rWGS) for Diagnosis of Genetic Disorders | 06.02.46 | | 1/1/2023 | | | 12/15/2022 | This is a New Policy. | | |
| New Policies | Spesolimab--sbzo (Spevigo®) | 08.01.97 | | 12/19/2022 | | | 12/19/2022 | This is a New Policy. | | |
| New Policies | Psychological Testing | 14.00.02 | 11/1/2022 10:00 AM | 1/1/2023 | | | 12/30/2022 | This is a New Policy. | | |
| New Policies | Applied Behavior Analysis (ABA) for the Treatment of Autism Spectrum Disorders (ASD) | 14.00.03 | 11/1/2022 10:00 AM | 1/1/2023 | | | 12/30/2022 | This is a New Policy. | | |
| New Policies | Betibeglogene Autotemcel [Beti-Cel (ZYNTEGLO®)] | 08.01.89 | | 1/1/2023 | | | 12/30/2022 | This is a New Policy. | | |
| New Policies | Electroconvulsive Therapy (ECT) | 14.00.01 | 11/1/2022 12:00 PM | 1/1/2023 | | | 12/30/2022 | This is a New Policy. | | |
| Updated Policies | Ostomy Supplies | 05.00.50n | 11/4/2022 9:00 AM | 12/5/2022 | | | 12/5/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Updated Policies | In Vivo Allergy Sensitivity Testing | 07.00.05i | | 12/5/2022 | | | 12/5/2022 | Medical Necessity Criteria | | |
| Updated Policies | Musculoskeletal Services (Independence) | 00.01.66g | | 11/6/2022 | | | 12/5/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria | | |
| Updated Policies | Insulin Pumps and Long-Term Interstitial Continuous Glucose Monitoring Systems | 05.00.79g | | 12/5/2022 | | | 12/5/2022 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Equipment, Supplies, and Pharmaceuticals for the Treatment of Diabetes | 05.00.05o | | 12/5/2022 | | | 12/5/2022 | Coverage and/or Reimbursement Position | | |
| Updated Policies | High-Technology Radiology Services (Independence) | 09.00.46am | | 11/6/2022 | | | 12/5/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Percutaneous Coronary Intervention, Coronary Angiography and Arterial Ultrasound (Independence) | 11.02.27f | | 11/6/2022 | | | 12/5/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | X-rays Associated with Fractures in the Office Setting | 00.03.09f | | 12/5/2022 | | | 12/5/2022 | Coverage and/or Reimbursement Position | | |
| Updated Policies | Transcutaneous Electrical Nerve Stimulators (TENS) and Associated Supplies | 05.00.74h | | 12/5/2022 | | | 12/5/2022 | Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | PPO Network Rules for Provision of Specialty Services for Durable Medical Equipment and Laboratory, Radiology, and Physical Medicine and Rehabilitative Services | 00.01.25bi | | 12/5/2022 | | | 12/5/2022 | Coverage and/or Reimbursement Position | | |
| Updated Policies | Never Events and Preventable Serious Adverse Events | 00.01.44j | | 12/5/2022 | | | 12/5/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related biosimilars | 08.01.32i | 11/18/2022 9:00 AM | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria | | |
| Updated Policies | In Vitro Allergy Testing | 06.02.26e | 11/18/2022 10:00 AM | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria | | |
| Updated Policies | Speech and Non-Speech Generating Devices | 05.00.32k | | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria | | |
| Updated Policies | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | 07.02.21j | | 12/19/2022 | | | 12/19/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Tafasitamab-cxix (Monjuvi®) | 08.01.81a | | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria | | |
| Updated Policies | Ado-Trastuzumab Emtansine (Kadcyla®) | 08.01.11h | | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria | | |
| Updated Policies | Reduction Mammoplasty | 11.08.02j | | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Scar Revision | 11.08.25n | | 12/19/2022 | | | 12/19/2022 | Coverage and/or Reimbursement Position;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Reimbursement for Radiopharmaceutical Agents for Professional Providers | 09.00.32ac | | 12/19/2022 | | | 12/19/2022 | Medical Coding | | |
| Updated Policies | Loncastuximab tesirine-lpyl (Zynlonta®) | 08.00.59b | | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria | | |
| Updated Policies | Polatuzumab vedotin-piiq (Polivy®) | 08.01.59d | | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria | | |
| Updated Policies | Cemiplimab-rwlc (Libtayo®) | 08.01.66b | | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria | | |
| Updated Policies | Enfortumab vedotin-ejfv (Padcev®) | 08.00.43d | | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria | | |
| Updated Policies | Avelumab (Bavencio®) | 08.01.64b | | 12/19/2022 | | | 12/19/2022 | Medical Necessity Criteria | | |
| Updated Policies | Chemical Peels | 11.08.08h | 9/26/2022 2:00 PM | 12/26/2022 | | | 12/26/2022 | Coverage and/or Reimbursement Position | | |
| Updated Policies | Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists and Related Biosimilars | 08.00.74q | | 1/1/2023 | | | 12/30/2022 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Gonadotropin-Releasing Hormone Agonist (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®) | 08.01.33h | | 1/2/2023 | | | 12/30/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Medical Evaluation and Management for Attention-Deficit Hyperactivity Disorder (ADHD) | 07.03.03h | 11/1/2022 10:00 AM | 1/1/2023 | | | 12/30/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Transcranial Magnetic Stimulation (TMS) | 07.03.22e | 11/1/2022 10:00 AM | 1/1/2023 | | | 12/30/2022 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Maintenance Treatment of Opioid or Alcohol Use Disorder | 08.01.37b | 11/1/2022 9:00 AM | 1/1/2023 | | | 12/30/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding | | |
| Updated Policies | Home-Use Light Box for the Treatment of Seasonal Affective Disorder (SAD) | 05.00.69c | 11/1/2022 10:00 AM | 1/1/2023 | | | 12/30/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Routine/Non-routine Vaccines | 08.01.04ab | | 1/1/2023 | | | 12/30/2022 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Evaluation and Management of Autism Spectrum Disorder (ASD) | 07.03.07y | 11/1/2022 10:00 AM | 1/1/2023 | | | 12/30/2022 | Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Durvalumab (Imfinzi®) | 08.01.65b | | 1/2/2023 | | | 12/30/2022 | Coverage and/or Reimbursement Position | | |
| Updated Policies | Intravenous Infliximab and Related Biosimilars | 08.00.34s | | 1/2/2023 | | | 12/30/2022 | Medical Necessity Criteria;Medical Coding | | |
| Updated Policies | Cranial Electrotherapy Stimulation | 05.00.80c | 11/1/2022 10:00 AM | 1/1/2023 | | | 12/30/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Acute Care Facility Inpatient Transfers | 12.04.04b | 11/1/2022 11:00 AM | 1/1/2023 | | | 12/30/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Wireless Capsule Endoscopy for Gastrointestinal (GI) Disorders | 07.05.02q | | 1/1/2023 | | | 12/30/2022 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Pertuzumab (Perjeta®) | 08.01.07i | | 1/2/2023 | | | 12/30/2022 | Medical Necessity Criteria | | |
| Updated Policies | eviCore Lab Management (Independence) | 06.02.52aa | 12/2/2022 11:00 AM | 1/1/2023 | | | 12/30/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Vagus Nerve Stimulation (VNS) | 11.15.16r | 11/1/2022 12:00 PM | 1/1/2023 | | | 12/30/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | 12/30/2022 | |
| Updated Policies | Deep Brain Stimulation (DBS) | 11.15.20q | 11/1/2022 12:00 PM | 1/1/2023 | | | 12/30/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Procedures for the Treatment of Gastroesophageal Reflux Disease (GERD) | 11.03.11q | | 1/2/2023 | | | 12/30/2022 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Wound Care: Skin Substitutes for the Treatment of Burns and Chronic, Non-Healing Wounds | 11.08.20ae | | 1/1/2023 | | | 12/30/2022 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Telemedicine Services | 00.10.41k | 11/1/2022 2:00 PM | 1/1/2023 | | | 12/30/2022 | Medical Necessity Criteria;Medical Coding | 12/30/2022 | |
| Updated Policies | Presumptive and Definitive Drug Testing in Substance Abuse and Pain Management Treatments | 06.02.44p | 11/1/2022 2:00 PM | 1/1/2023 | | | 12/30/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Therapeutic Drug Monitoring for Antidepressants, Antipsychotics, or Antiepileptics | 06.02.55a | 11/1/2022 2:00 PM | 1/1/2023 | | | 12/30/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Pharmacogenetic Testing to Determine Drug Sensitivity (Independence Administrators) | 06.02.30f | 11/1/2022 2:00 PM | 1/1/2023 | | | 12/30/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®) | 08.01.80a | 11/1/2022 9:00 AM | 1/1/2023 | | | 12/30/2022 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Fetal Surgery | 11.00.03l | | 1/2/2023 | | | 12/30/2022 | Medical Necessity Criteria | | |
| Updated Policies | Cetuximab (Erbitux®) | 08.00.67n | | 1/2/2023 | | | 12/30/2022 | Medical Necessity Criteria | | |
| Coding Update | Genetic Testing (Independence Administrators) | 06.02.35ah | | 10/1/2022 | | | 12/7/2022 | | | |
| Coding Update | Self-Administered Drugs | 08.00.78al | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents | 08.01.08k | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Ambulatory Electrocardiography (AECG) Monitoring and Mobile Cardiac Outpatient Telemetry (MCOT) Monitoring | 07.02.21k | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Bone Mineral Density (BMD) Testing | 09.00.04m | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Equipment, Supplies, and Pharmaceuticals for the Treatment of Diabetes | 05.00.05p | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Insulin Pumps and Long-Term Interstitial Continuous Glucose Monitoring Systems | 05.00.79h | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Esophagogastroduodenoscopy (EGD) and Endoscopic Retrograde Cholangiopancreatography (ERCP) | 07.02.22d | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Artificial Intervertebral Lumbar Disc Insertion | 11.15.31b | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Percutaneous Coronary Intervention, Coronary Angiography and Arterial Ultrasound (Independence) | 11.02.27g | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Percutaneous Vertebroplasty, Kyphoplasty and Sacroplasty (Independence Administrators) | 11.14.10t | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®) | 08.01.41e | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Aqueous Shunts, Microstents, Viscocanalostomy, and Canaloplasty for the Treatment of Glaucoma | 11.05.16l | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Dermabrasion for Rhinophyma, Septoplasty, Rhinoplasty, and Septorhinoplasty | 11.16.01j | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Fecal Microbiota Transplantation (FMT) | 07.05.08c | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Orthoptic/Pleoptic Training | 07.13.01j | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | 08.00.66s | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Diagnostic Radiology Services Included in Capitation | 00.03.02ad | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Laboratory Services for Members Enrolled in Health Maintenance Organization (HMO) or Health Maintenance Organization Point-of-Service (HMO-POS) Products | 00.03.07ai | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Risankizumab-rzaa (Skyrizi®) for Intravenous Use | 08.01.95a | | 1/1/2023 | | | 12/30/2022 | | | |
| Coding Update | Bortezomib (Bortezomib for Injection, Velcade®) | 08.00.73o | | 1/1/2023 | | | 12/30/2022 | | | |
